[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578808":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":32,"responsibleParty":155,"collaborators":11,"id":157,"slug":158,"hasResults":159,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":11,"eligibilityCriteria":163,"healthyVolunteers":159,"sex":164,"minAge":165,"maxAge":11,"enrollmentInfo":166,"targetDuration":11,"studyType":169,"phases":170,"briefSummary":172,"conditions":173,"keywords":11,"overallStatus":35,"whyStopped":11,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":185},{"fullName":5,"class":6},"Ono Pharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ONO-7428","EXPERIMENTAL",null,[13],"Drug: ONO-7428",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","Specified dose on specified days",[9],[20],{"name":21,"affiliation":5,"role":22},"Project Leader","STUDY_DIRECTOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"North America Clinical Trial Support Desk","CONTACT","+18665877745(Toll-Free)","clinical_trial@ono-pharma.com",{"name":30,"role":26,"phone":31,"phoneExt":11,"email":28},"International Clinical Trial Support Desk","+17162141777(Standard)",[33,46,55,64,73,82,90,99,107,116,123,131,140,148,152],{"facility":34,"status":35,"city":36,"state":37,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":11},"Nagoya University Hospital","RECRUITING","Nagoya","Aichi-ken","Japan","JP",{"type":41,"coordinates":42},"Point",[43,44],136.90641,35.18147,{"lat":44,"lon":43},{"facility":47,"status":35,"city":48,"state":49,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":50,"geoPoint":54,"contacts":11},"National Cancer Center Hospital East","Kashiwa","Chiba",{"type":41,"coordinates":51},[52,53],139.97732,35.86224,{"lat":53,"lon":52},{"facility":56,"status":35,"city":57,"state":58,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":59,"geoPoint":63,"contacts":11},"Kurume University Hospital","Kurume","Fukuoka",{"type":41,"coordinates":60},[61,62],130.51667,33.31667,{"lat":62,"lon":61},{"facility":65,"status":35,"city":66,"state":67,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":68,"geoPoint":72,"contacts":11},"Hyogo Medical University Hospital","Nishinomiya","Hyōgo",{"type":41,"coordinates":69},[70,71],135.33199,34.71562,{"lat":71,"lon":70},{"facility":74,"status":35,"city":75,"state":76,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":77,"geoPoint":81,"contacts":11},"Kitasato University Hospital","Sagamihara","Kanagawa",{"type":41,"coordinates":78},[79,80],139.24167,35.56707,{"lat":80,"lon":79},{"facility":83,"status":35,"city":84,"state":76,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":85,"geoPoint":89,"contacts":11},"Kanagawa Cancer Center","Yokohama",{"type":41,"coordinates":86},[87,88],139.65,35.43333,{"lat":88,"lon":87},{"facility":91,"status":35,"city":92,"state":93,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":94,"geoPoint":98,"contacts":11},"Kochi Medical School Hospital","Nankoku","Kochi",{"type":41,"coordinates":95},[96,97],133.64937,33.56943,{"lat":97,"lon":96},{"facility":100,"status":35,"city":101,"state":101,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":102,"geoPoint":106,"contacts":11},"Kyoto University Hospital","Kyoto",{"type":41,"coordinates":103},[104,105],135.75385,35.02107,{"lat":105,"lon":104},{"facility":108,"status":35,"city":109,"state":110,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":111,"geoPoint":115,"contacts":11},"Kansai Medical University Hospital","Hirakata","Osaka",{"type":41,"coordinates":112},[113,114],135.64914,34.81352,{"lat":114,"lon":113},{"facility":117,"status":35,"city":110,"state":110,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":118,"geoPoint":122,"contacts":11},"Osaka International Cancer Institute",{"type":41,"coordinates":119},[120,121],135.50107,34.69379,{"lat":121,"lon":120},{"facility":124,"status":35,"city":125,"state":110,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":126,"geoPoint":130,"contacts":11},"Kindai University Hospital","Sakai",{"type":41,"coordinates":127},[128,129],135.46653,34.58216,{"lat":129,"lon":128},{"facility":132,"status":35,"city":133,"state":134,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":135,"geoPoint":139,"contacts":11},"Saitama Medical University International Medical Center","Hidaka","Saitama",{"type":41,"coordinates":136},[137,138],139.36233,35.91664,{"lat":138,"lon":137},{"facility":141,"status":35,"city":142,"state":134,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":143,"geoPoint":147,"contacts":11},"Saitama Cancer Center","Shinden",{"type":41,"coordinates":144},[145,146],139.62486,35.99971,{"lat":146,"lon":145},{"facility":149,"status":35,"city":150,"state":151,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital","Bunkyō-Ku","Tokyo",{"facility":153,"status":35,"city":154,"state":151,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"The Cancer Institute Hospital Of JFCR","Koto-Ku",{"type":156,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100578808","phase-1-a-study-of-ono-7428-in-participants-with-unresectable-advanced-or-recurrent-solid-tumors-100578808",false,"NCT06816108","A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors","A Phase I, Open-label, Dose Escalation Study to Evaluate the Tolerability and Safety of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors","Inclusion Criteria:\n\n1. Participants with histologically or cytologically confirmed unresectable advanced or recurrent solid tumors.\n\n   \\[Backfill cohort only\\] Participants with histologically or cytologically confirmed Stage IIIB, IIIC, IV, or recurrent NSCLC according to UICC-TNM classification.\n2. Participants who are refractory or intolerant to standard therapy.\n3. Participants with a tumor type for which anti-PD-(L)1 antibodies have been approved and who have previously treated with anti-PD-(L)1 antibody containing regimen.\n4. Participants with Eastern Cooperative Oncology Group Performance Status 0 or 1.\n5. Participants with tumor tissue samples available for biomarker testing.\n\nExclusion Criteria:\n\n1. Participants with a complication or history of severe hypersensitivity to any other antibody drugs.\n2. Participants with concurrent autoimmune disease or a history of chronic or recurrent autoimmune disease\n3. Participants with severe peritoneal dissemination.\n4. Participants with pericardial fluid, pleural effusion, or ascites requiring treatment.\n5. Participants with uncontrolled tumor-related pain.\n6. Participants with active or history of interstitial lung disease or pulmonary fibrosis.","ALL","18 Years",{"count":167,"type":168},60,"ESTIMATED","INTERVENTIONAL",[171],"PHASE1","This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.",[174,175],"Solid Tumor","NSCLC","2026-01-09",{"date":178,"type":179},"2026-01-12","ACTUAL",{"date":181,"type":179},"2025-04-21",{"date":183,"type":168},"2029-07",{"name":5,"class":6},15]